Your browser doesn't support javascript.
Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates.
Yao, Yan-Feng; Wang, Ze-Jun; Jiang, Ren-Di; Hu, Xue; Zhang, Hua-Jun; Zhou, Yi-Wu; Gao, Ge; Chen, Ying; Peng, Yun; Liu, Mei-Qin; Zhang, Ya-Nan; Min, Juan; Lu, Jia; Gao, Xiao-Xiao; Guo, Jing; Peng, Cheng; Shen, Xu-Rui; Li, Qian; Zhao, Kai; Yang, Lian; Wan, Xin; Zhang, Bo; Wang, Wen-Hui; Wu, Jia; Zhou, Peng; Yang, Xing-Lou; Shen, Shuo; Shan, Chao; Yuan, Zhi-Ming; Shi, Zheng-Li.
  • Yao YF; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Wang ZJ; Wuhan Institute of Biological Products Co. Ltd, Jiangxia District, Wuhan, 430024, China.
  • Jiang RD; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Hu X; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Zhang HJ; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Zhou YW; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Gao G; Department of Forensic Medicine, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430074, China.
  • Chen Y; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Peng Y; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Liu MQ; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Zhang YN; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Min J; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Lu J; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Gao XX; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Guo J; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Peng C; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Shen XR; Wuhan Institute of Biological Products Co. Ltd, Jiangxia District, Wuhan, 430024, China.
  • Li Q; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Zhao K; Wuhan Institute of Biological Products Co. Ltd, Jiangxia District, Wuhan, 430024, China.
  • Yang L; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Wan X; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Zhang B; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Wang WH; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Wu J; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Zhou P; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Yang XL; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Shen S; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430074, China.
  • Shan C; Wuhan Institute of Biological Products Co. Ltd, Jiangxia District, Wuhan, 430024, China.
  • Yuan ZM; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Shi ZL; Wuhan Institute of Biological Products Co. Ltd, Jiangxia District, Wuhan, 430024, China.
Virol Sin ; 36(5): 879-889, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1174014
ABSTRACT
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused more than 96 million infections and over 2 million deaths worldwide so far. However, there is no approved vaccine available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease causative agent. Vaccine is the most effective approach to eradicate a pathogen. The tests of safety and efficacy in animals are pivotal for developing a vaccine and before the vaccine is applied to human populations. Here we evaluated the safety, immunogenicity, and efficacy of an inactivated vaccine based on the whole viral particles in human ACE2 transgenic mouse and in non-human primates. Our data showed that the inactivated vaccine successfully induced SARS-CoV-2-specific neutralizing antibodies in mice and non-human primates, and subsequently provided partial (in low dose) or full (in high dose) protection of challenge in the tested animals. In addition, passive serum transferred from vaccine-immunized mice could also provide full protection from SARS-CoV-2 infection in mice. These results warranted positive outcomes in future clinical trials in humans.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Animals Language: English Journal: Virol Sin Journal subject: Virology Year: 2021 Document Type: Article Affiliation country: S12250-021-00376-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Animals Language: English Journal: Virol Sin Journal subject: Virology Year: 2021 Document Type: Article Affiliation country: S12250-021-00376-w